{
  "ptid_time": "022_S_4173_2011-09-13",
  "img_path": "/data/qiuhui/data/adni/images/022_S_4173/2011-09-13/t1.nii.gz",
  "img_finding": "Image findings: ventricular volume measures 15,987 mm³, 28.4% below the reference mean. With a Z-score of -0.71 (23.8th percentile), this represents normal volume ; hippocampal volume measures 6,820 mm³, 11.3% below the reference mean. With a Z-score of -1.26 (10.3th percentile), this represents mild atrophy; whole brain volume measures 961,263 mm³, 6.6% below the reference mean. With a Z-score of -0.82 (20.6th percentile), this represents normal volume ; entorhinal cortex volume measures 2,518 mm³, 35.3% below the reference mean. With a Z-score of -2.74 (0.3th percentile), this represents significant atrophy; fusiform gyrus volume measures 18,044 mm³, 0.9% below the reference mean. With a Z-score of -0.10 (45.9th percentile), this represents normal volume ; middle temporal gyrus volume measures 20,052 mm³, 2.3% below the reference mean. With a Z-score of -0.20 (42.0th percentile), this represents normal volume . ",
  "text_data": "Age is 69.8 years. Gender is Female. Education: 12 years. Handedness: Right. Race: White. Medical history: Head, Eyes, Ears, Nose and Throat; Cardiovascular; Musculoskeletal; Gastrointestinal; Smoking. MMSE: 30.0. MoCA: 28.0. Logical Memory: 16.0. Laboratory findings: LDH: 233.00 (significant elevated); Triglycerides (GPO): 241.00 (significant elevated); Cholesterol (High Performance): 301.00 (profound elevated). APOEε4 alleles: 0.0. Biomarker levels: Florbetapir (AV45): 1.10 SUVR (normal ); Amyloid beta: 1358.00 pg/mL (normal ); Total tau: 161.10 pg/mL (mild reduced); Phosphorylated tau: 13.03 pg/mL (mild reduced). ",
  "true_diagnosis": "Diagnosis: CN.",
  "gpt_diagnosis": "**Reasoning:** The data shows significant atrophy in the entorhinal cortex (Z-score -2.74, 0.3rd percentile) and mild hippocampal atrophy (Z-score -1.26, 10.3rd percentile), both key regions in Alzheimer's pathology. However, cognitive scores (MMSE 30, MoCA 28) are intact, and biomarkers (Aβ normal, AV45 normal) do not support amyloid pathology.  \n**Diagnosis:** **Mild Cognitive Impairment (MCI)** (due to structural changes without overt cognitive decline)  \n**Confidence:** **Medium** (biomarkers contradict typical AD, but entorhinal atrophy is concerning)  \n\n*Alternative considerations:*  \n- If cognitive complaints were present, **prodromal AD** could be considered despite normal Aβ (entorhinal atrophy is highly specific).  \n- If follow-up shows cognitive decline, confidence in **neurodegenerative etiology** would increase.  \n- **Low confidence in AD** due to normal amyloid.",
  "timestamp": "2025-07-26T02:17:06.058820"
}